The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the op...

AIM To understand the impact of Crohn's disease (CD) on various aspects of daily life from the perspective of patients living with CD. Awareness of the disease and biologic therapies, patient satisfaction and adherence, and physician (provider) relationships were also assessed. BACKGROUND CD is a chronic, inflammatory, autoimmune disorder of the gastrointestinal tract that substantially impac...

Biologic agents are targeted immune modulating agents that have been widely used in the treatment of inflammatory and neoplastic conditions with favorable results. The purpose of this review is to provide an update on the biologic agents that have been used in the treatment of diseases that affect the oral mucosa. Identification of relevant data, case reports and case series was performed using...

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. These agents provide therapeutic alternatives to traditional topical and systemic therapies. Alefacept, the first such biologic agent, was approved by the US FDA in January 2003 for the treatment of chronic plaque psoriasis. This review will discuss data from clinical trials that have prov...

Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents: A Retrospective Analysis From anAcademicMedical Center Pityriasis rubra pilaris (PRP) is characterized by hyperkeratoticpapules,palmoplantarkeratoderma, andwidespreaderythema with islands of sparing. Treatment is challenging, and a standard therapeutic protocol doesnot exist. Given thepaucity of available therapeutic data...

Inflammatory bowel disease (IBD) coexists in up to 80% of patients with primary sclerosing cholangitis (PSC). PSC-IBD tends be mild and responsive mesalamine most patients. However, some may require immunosuppressive (IMM) or biologic therapy treat PSC-IBD. The aims this study are investigate the rates, predictors, outcomes biologic/IMM treatment This was a single center, retrospective PSC from...

INTRODUCTION Pneumocystis pneumonia (PCP) is one of the most prevalent opportunistic infections in patients undergoing immunosuppressive therapy. In this article, we discuss risk factors for PCP development in patients with rheumatoid arthritis (RA) during the course of biologic therapy and describe a prophylactic treatment for PCP with trimethoprim/sulfamethoxazole (TMP/SMX). We also evaluate ...